P2RY12 and coronary artery disorder: The P2Y12 inhibitor or aspirin monotherapy as secondary prevention in patients with coronary artery disease: an individual patient data meta-analysis of randomized trials (PANTHER) trial assessed the role of long-term P2Y12 monotherapy compared to aspirin monotherapy for the prevention of recurrent events in patients with CAD [81].